Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).

Young G, Shapiro AD, Walsh CE, Gruppo RA, Gut RZ, Cooper DL.

Haemophilia. 2012 May;18(3):392-9. doi: 10.1111/j.1365-2516.2011.02704.x. Epub 2011 Dec 16.

PMID:
22171621
3.
4.

A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.

Mehta DA, Oladapo AO, Epstein JD, Novack AR, Neufeld EJ, Hay JW.

J Manag Care Spec Pharm. 2016 Feb;22(2):149-57. doi: 10.18553/jmcp.2016.22.2.149.

5.

Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE).

Valentino LA, Walsh CE, Reding MT, Young GA, Levendoglu-Tugal O, Cooper DL.

Haemophilia. 2012 Jul;18(4):554-60. doi: 10.1111/j.1365-2516.2012.02762.x. Epub 2012 Feb 20.

PMID:
22348407
6.

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.

Parameswaran R, Shapiro AD, Gill JC, Kessler CM; HTRS Registry Investigators.

Haemophilia. 2005 Mar;11(2):100-6.

PMID:
15810910
8.

Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).

Neufeld EJ, Kessler CM, Gill JC, Wilke CT, Cooper DL; Htrs Investigators.

Haemophilia. 2011 Jul;17(4):650-6. doi: 10.1111/j.1365-2516.2010.02483.x. Epub 2011 Feb 7.

PMID:
21299750
9.

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.

Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E.

Thromb Haemost. 1998 Dec;80(6):912-8.

PMID:
9869160
11.

Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.

Salaj P, Kubes R, Cetkovsky P, Capova I, Penka M, Ovesná P, Mesterton J, Lindgren P.

Thromb Res. 2014 Feb;133(2):162-7. doi: 10.1016/j.thromres.2013.11.002. Epub 2013 Nov 14.

PMID:
24321420
12.

Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia.

Morfini M, Bjerre J.

Haemophilia. 2011 Nov;17(6):860-6. doi: 10.1111/j.1365-2516.2011.02498.x. Epub 2011 Mar 4.

PMID:
21371194
13.

How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.

Brown SA, Barnes C, Curtin J, Dunkley S, Ockelford P, Phillips J, Rowell J, Smith M, Tran H; Hematology working group.

Intern Med J. 2012 Nov;42(11):1243-50. doi: 10.1111/j.1445-5994.2012.02942.x. Erratum in: Intern Med J. 2013 Jan;43(1):106.

PMID:
23157518
14.

On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.

Sørensen B, Dargaud Y, Kenet G, Lusher J, Mumford A, Pipe S, Tiede A.

Haemophilia. 2012 Mar;18(2):255-62. doi: 10.1111/j.1365-2516.2011.02612.x. Epub 2011 Jul 19.

PMID:
21771206
15.

Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries.

Bensadok M, Almomen A, Alzoebie A, Benchikh El Fegoun S, Wali Y, Hamzy F, Mehalhal NG, Grifi F, Hamdi S, Mesli N, Owaidah T, Saad HA, Mansour NS, Touhami H.

Blood Coagul Fibrinolysis. 2017 Mar;28(2):145-151. doi: 10.1097/MBC.0000000000000564.

17.

Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.

Valentino LA, Cooper DL, Goldstein B.

Haemophilia. 2011 Jul;17(4):579-89. doi: 10.1111/j.1365-2516.2010.02460.x. Epub 2011 Feb 7. Review.

PMID:
21294815
18.

Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004-2008).

Neufeld EJ, Saxena K, Kessler CM, Cooper DL; HTRS Investigators.

Pediatr Blood Cancer. 2013 Jul;60(7):1178-83. doi: 10.1002/pbc.24472. Epub 2013 Jan 17.

PMID:
23335449
19.

Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.

Petrini P, Klementz G.

Blood Coagul Fibrinolysis. 1998 Mar;9 Suppl 1:S143-6.

PMID:
9819046
20.

Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.

Joshi AV, Stephens JM, Munro V, Mathew P, Botteman MF.

Curr Med Res Opin. 2006 Jan;22(1):23-31.

PMID:
16393427

Supplemental Content

Support Center